Valuation: Design Therapeutics, Inc.

Market Cap 785M 686M 633M 584M 1.1B 75.6B 1.12B 7.57B 2.98B 37.03B 2.95B 2.88B 127B P/E 2026 *
-9.27x
P/E 2027 * -7.66x
Enterprise Value 605M 529M 488M 450M 847M 58.25B 866M 5.83B 2.29B 28.53B 2.27B 2.22B 98.21B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Design Therapeutics, Inc.

1 day-0.32%
1 week-17.25%
Current month-13.13%
1 month+1.05%
3 months-4.19%
6 months+35.45%
Current year+34.01%
1 week 12.19
Extreme 12.19
15.2
1 month 12.19
Extreme 12.19
15.86
Current year 8.23
Extreme 8.23
17.25
1 year 3.76
Extreme 3.76
17.25
3 years 1.94
Extreme 1.94
17.25
5 years 1.94
Extreme 1.94
26.3
10 years 1.94
Extreme 1.94
50.5
Manager TitleAgeSince
Chief Executive Officer 56 2023-08-24
Chief Tech/Sci/R&D Officer - 2021-05-31
Chief Operating Officer 46 2020-12-31
Director TitleAgeSince
Chairman 56 2017-12-17
Director/Board Member 71 2019-06-30
Director/Board Member 49 2020-01-31
Date Insider Type Main position Quantity % Market Cap.
6/9/26 Free

Director

30,000 0.0480%
6/9/26 Free

Director

30,000 0.0480%
6/9/26 Free

Director

30,000 0.0480%
Change 5-day change 1-year change 3-year change Capi.($)
-0.32%-17.25%+215.83%+78.81% 785M
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average +0.02%-1.70%+82.63%+96.25% 24.44B
Weighted average by Cap. -0.05%-0.24%+79.91%+123.16%

Financials

2026 *2027 *
Net sales - -
Net income -85.49M -74.71M -68.94M -63.55M -120M -8.23B -122M -824M -324M -4.03B -321M -314M -13.88B -116M -101M -93.64M -86.31M -163M -11.18B -166M -1.12B -440M -5.48B -436M -427M -18.85B
Net Debt -180M -157M -145M -134M -252M -17.35B -258M -1.74B -683M -8.5B -677M -662M -29.26B -106M -92.72M -85.56M -78.87M -149M -10.22B -152M -1.02B -402M -5B -398M -390M -17.23B
Logo Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Employees
54
Date Price Change Volume
26-07-17 US$12.57 -0.32% 468,167
26-07-16 US$12.61 -6.73% 900,806
26-07-15 US$13.52 -1.10% 396,307
26-07-14 US$13.67 -1.34% 582,411
26-07-13 US$13.86 -8.79% 654,659
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
12.57USD
Average target price
21.00USD
Spread / Average Target
+67.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DSGN Stock